Early Intensive Therapy with Autologous Stem Cell Transplantation in High-Risk Hodgkin's Disease: Long-Term Follow-Up in 35 Cases

References

• Hoppe R.T. Development of effective salvage treatment programs for Hodgkin's disease: An ongoing challenge. Blood 1991; 77: 2093–2095
   PubMed Web of Science ®Google Scholar
• Nademanee A., O'Donnell M.R., Snyder D.S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381–1390
   PubMed Web of Science ®Google Scholar
• Jagannath S., Armitage J.O., Dicke K.A., et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, etoposide with autotransplan-tation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179–185
   PubMed Web of Science ®Google Scholar
• Chopra R., McMillan A.K., Linch D.C., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Reece D.E., Connors J.M., Spinelli J.J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Desch C.E., Lasala M.R., Smith T.J., et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clinical Oncol 1992; 10: 200–209
   PubMed Web of Science ®Google Scholar
• Yuen A.R., Rosenberg S.A., Hoppe R.T., et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Homing S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Bierman P.J., Vose J.M., Armitage J.O. Autologous transplantation for Hodgkin's disease: Coming of age'?. Blood 1994; 83: 1161–1164
   PubMed Web of Science ®Google Scholar
• Carella A.M., Carlier P., Congiu A., et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP-ABVD protocol. Bone Marrow Transplant 1991; 8: 99–103
   PubMed Web of Science ®Google Scholar
• Moreau P., Milpied N., Méchinaud-Lacroix F., et al. Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leak Lymph 1993; 12: 51–58
   PubMed Web of Science ®Google Scholar
• Fleury J., Legros M., Colombat P., et al. High-dose therapy and autologous bone marrow transplantation in first complete or partial response for poor prognosis Hodgkin's disease. Leuk Lymph 1996; 20: 259–266
   PubMed Web of Science ®Google Scholar
• Sureda A., Mataix R., Hernandez-Navarro, et al. Autologous stem cell transplantation for poor-prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO coopertive group. Bone Marrow Transplant 1997; 20: 283–288
   PubMed Web of Science ®Google Scholar
• Straus D.J., Gaynor J.J., Myers J., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Gobbi P.G., Cavalli C., Federico M., et al. Hodgkin's disease prognosis: A directly predictive equation. Lancet 1986; i: 675–679
   Google Scholar
• Hasenclever D., Diehl V. The international prognostic factors project on advanced Hodgkin's disease: a prognostic index, but no very high risk group. Ann Oncol 1996; 7(Suppl 3)21a, (abstr)
   Google Scholar
• Proctor S.J., Taylor P., Donnan P., et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991; 27: 624–629
   PubMed Web of Science ®Google Scholar
• Wagstaff J., Gregory W.M., Swindell R., et al. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centers. Br J Cancer 1988; 58: 487–492
   PubMed Web of Science ®Google Scholar
• Kuentz M., Reyes F., Brun B., et al. Early response to chemotherapy as a prognostic factor in Hodgkin's disease. Cancer 1983; 52: 780–785
   PubMed Web of Science ®Google Scholar
• Levis A., Vitolo U., Ciocca Vasino A., et al. Predictive value of early response to chemotherapy in high risk stages II and III Hodgkin's disease. Cancer 1987; 60: 1713–1719
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadona G., Bonfante V., et al. Alternating drug combination in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–775
   PubMed Web of Science ®Google Scholar
• Lukes R.J., Buttler J.J. The pathology and nomenclature for Hodgkin's disease. Cancer Res 1966; 26: 1063–1081
   PubMed Web of Science ®Google Scholar
• Linch D.C., Knott L.J., Patterson K.G., et al. Bone marrow processing and cryopreservation. J Clin Pathol 1982; 35: 186–190
   PubMed Web of Science ®Google Scholar
• Fermand J.P., Levy Y., Gerota, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem ceils autologous grafts. Blood 1989; 73: 20–23
   PubMed Web of Science ®Google Scholar
• Moreau P., LeTortorec S., Mane B., et al. Granulocyte colony-stimulating factor administered from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization. Nouv Rev Fr Hematol. 1994; 36: 455–458
   PubMedGoogle Scholar
• Faucher C., LeCorroler A.G., Chabannon C., et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533–536
   PubMed Web of Science ®Google Scholar
• Chen J.L., Osborne B.M., Buttler J.J. Residual fibrous masses in treated Hodgkin's disease. Cancer 1987; 60: 407–413
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 157–181
   Web of Science ®Google Scholar
• Burgers J.M.V., Somers R., Henry-Amar M., et al. Management of relapse and survival in advanced stage Hodgkin's disease: The EORTC experience. Ann Oncol 1991; 2(suppl.2)63–66
   PubMedGoogle Scholar
• Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• Viviani S., Bonadonna G., Santoro A., et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996; 14: 1421–1430
   PubMed Web of Science ®Google Scholar
• Salloum E., Doria R., Schubert W., et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996; 14: 2435–2443
   PubMed Web of Science ®Google Scholar
• Miller J.S., Arthur D.C., Litz C.E., et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83: 3780–3786
   PubMed Web of Science ®Google Scholar
• Traweek T., Slovak M.L., Nademanee A.P., et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84: 957–963
   PubMed Web of Science ®Google Scholar
• Darrington D.L., Vose J.M., Anderson J.R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Stone R.M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Pihkala J., Saarinen U.M., Lundstrom U., et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant 1994; 13: 149–155
   PubMed Web of Science ®Google Scholar
• Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart after treatment for Hodgkin's disease. JAMA 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar
• Corn B.W., Trock B.J., Goodman R.L. Irradiation-related ischemic heart disease. J Clin Oncol 1990; 8: 741–750
   PubMed Web of Science ®Google Scholar
• Phillips G.L., Wolff S.N., Herzig R.H., et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086–2092
   PubMed Web of Science ®Google Scholar
• Horning S.J., Negrin R.S., Chao N., et al. Fractionated total-body irradiation, etoposide and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552–2558
   PubMed Web of Science ®Google Scholar
• Bonnadonna G., Santoro A., Gianni A.M., et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 1991; 2(Suppl 1)9–16
   Google Scholar
• Kunkel L., Tung P., Ireland P., Schiller G., Territo M. Two-staged autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995; 14: 322a, (abstr)
   Google Scholar
• Ahmed T., Lake D.E., Beer M., et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant. 1997; 19: 449–454
   PubMed Web of Science ®Google Scholar
• Bartlett N.L., Rosenberg S.A., Hoppe R.T., et al. Brief chemotherapy, Stanford V., and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J. Clin Oncol 1995; 13: 1080–1088
   PubMed Web of Science ®Google Scholar
• Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Hancock B.W., Vaughan Hudson G., Vaughan Hudson B., et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation trial. J Clin Oncol 1992; 10: 1252–1258
   PubMed Web of Science ®Google Scholar
• Longo D.L., Duffey P.L., DeVita V.T., et al. Treatment of advanced-stage Hodgkin's disease: Alternating non crossresistant MOPP/CABS is not superior to MOPP. J. Clin Oncol 1991; 9: 1409–1420
   PubMed Web of Science ®Google Scholar
• Fermé C., Lepage E., Brice P., et al. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiation Oncology Biol Phys 1993; 26: 397–405
   PubMed Web of Science ®Google Scholar
• Somers R., Carde P., Henry-Amar H., et al. A randomized study in stage IHB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma cooperative group and group Pierre-et-Marie Curie controlled clinical trial. J Clin Oncol 1994; 12: 279–287
   PubMed Web of Science ®Google Scholar
• Connors J.M., Klimo P., Adams G., et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15: 1638–1645
   PubMed Web of Science ®Google Scholar
• Duggan D., Petroni G., Johnson J., et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease-a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 12a, (abstract)
   Google Scholar